Investigating the Effects of O-GlcNAc Modifications in Parkinson’s Disease Using Semisynthetic α-Synuclein
- 225 Downloads
α-Synuclein is a small aggregation-prone protein associated with Parkinson’s disease (PD). The protein’s biochemical and biophysical properties can be heavily influenced by various types of posttranslational modification (PTMs) such as phosphorylation, ubiquitination, and glycosylation. To understand the site-specific effects of various PTMs have on the protein and its aggregation, obtaining a homogeneous sample of the protein of interest with the specific modification of interest is key. Expressed protein ligation (EPL) has emerged as robust tool for building synthetic proteins bearing site-specific modifications. Here, we outline our approach for building α-synuclein with site specific O-GlcNAc modifications, an intracellular subtype of glycosylation that has been linked to the inhibition of protein aggregation. More specifically, we provide specific protocols for the synthesis of α-synuclein bearing an O-GlcNAc modification at threonine 72, termed α-synuclein(gT72). However, this general approach utilizing two recombinant fragments and one synthetic peptide is applicable to other sites and types of modifications and should be transferable to various other protein targets, including aggregation prone proteins like tau and TDP-43.
Key wordsα-synuclein Posttranslational modification Synthetic protein chemistry Expressed protein ligation O-GlcNAc
This research was supported by the National Institutes of Health (Grant R01GM114537 to M.R.P.).
- 10.Oueslati A, Fournier M, Lashuel HA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res. 183:115–145. https://doi.org/10.1016/S0079-6123(10)83007-9CrossRefPubMedGoogle Scholar
- 13.Wang Z, Udeshi ND, O'Malley M, Shabanowitz J, Hunt DF, Hart GW (2010) Enrichment and site mapping of O-linked N-acetylglucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation mass spectrometry. Mol Cell Proteomics 9:153–160. https://doi.org/10.1074/mcp.M900268-MCP200CrossRefPubMedGoogle Scholar
- 14.Alfaro JF, Gong C-X, Monroe ME, Aldrich JT, Clauss TRW, Purvine SO et al (2012) Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc Natl Acad Sci USA 109:7280–7285. https://doi.org/10.1073/pnas.1200425109CrossRefPubMedGoogle Scholar
- 16.Wang S, Yang F, Petyuk VA, Shukla AK, Monroe ME, Gritsenko MA et al (2017) Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer’s disease. J Pathol 243:78–88. https://doi.org/10.1002/path.4929CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Levine PM, Galesic A, Balana AT, Mahul-Mellier A-L, Navarro MX, De Leon CA et al (2019) α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson’s disease. Proc Natl Acad Sci USA 116:1511–1519. https://doi.org/10.1073/pnas.1808845116CrossRefPubMedGoogle Scholar
- 31.De Leon CA, Lang G, Saavedra MI, Pratt MR (2018) Simple and efficient preparation of O- and S-GlcNAcylated amino acids through InBr3-catalyzed synthesis of β-N-acetylglycosides from commercially available reagents. Org Lett 20:5032–5035. https://doi.org/10.1021/acs.orglett.8b02182CrossRefPubMedPubMedCentralGoogle Scholar